ATLAS / Macro Radar / Reporting / ENGN

enGene Therapeutics Inc. (ENGN) reporting calendar

enGene Therapeutics Inc. files periodic reports with the SEC as ENGN on Nasdaq. Atlas tracks 11 filed reports for this issuer, each linked to its original EDGAR accession.

Next window
4 Sep 2026 – 18 Sep 2026
Latest report
10-Q
Period ended
30 Apr 2026
Filed
15 Jun 2026
Reports on record
11

How this window is derived. Derived from this issuer's own filing history: 9 periods at a median 92-day cadence, filed a median 42 days after period end. The SEC does not publish forward reporting dates and Atlas does not estimate one.

Open ENGN market profile Latest filing on SEC EDGAR ↗ Biological Products, (No Diagnostic Substances) reporting datesAll Nasdaq reporting dates

Filed periodic reports

FormPeriod endedFiledLagSEC accession
10-Q30 Apr 202615 Jun 202646 days0001193125-26-270386
10-Q31 Jan 20269 Mar 202637 days0001193125-26-097541
10-K31 Oct 202522 Dec 202552 days0001193125-25-328743
10-Q31 Jul 202511 Sep 202542 days0000950170-25-114224
10-Q30 Apr 202512 Jun 202543 days0000950170-25-085143
10-Q31 Jan 202510 Mar 202538 days0000950170-25-036281
10-K31 Oct 202419 Dec 202449 days0000950170-24-138472
10-Q31 Jul 202410 Sep 202441 days0000950170-24-105180
10-Q30 Apr 202414 Jun 202445 days0000950170-24-073330
10-Q31 Jan 202411 Mar 202440 days0000950170-24-029413
10-K31 Oct 202329 Jan 202490 days0000950170-24-008125

Source: SEC EDGAR company submissions for CIK 0001980845. Atlas publishes filed facts only. The SEC does not publish forward reporting dates, so no announced future date is claimed here.